|
Lennox-Gastaut syndrome
|
0.500 |
GeneticVariation
|
disease |
ORPHANET |
Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathy.
|
16249883 |
2006 |
|
Lennox-Gastaut syndrome
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
|
23329067 |
2013 |
|
Epileptic encephalopathy
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathy.
|
16249883 |
2006 |
|
Epileptic encephalopathy
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
|
23329067 |
2013 |
|
Langer-Giedion Syndrome
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
|
23329067 |
2013 |
|
MACROCEPHALY AND EPILEPTIC ENCEPHALOPATHY
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Epileptic drop attack
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Tonic - clonic seizures
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Atypical absence seizure
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Autistic behavior
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Generalized myoclonic seizures
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
All of these indicated <b>J30-8</b> as proved isoform-selective JNK3 inhibitors that might serve as a useful tool for further JNK3 studies with AD as well as for the development of JNK3 inhibitors for the potential treatment of neurodegenerative diseases.
|
31268308 |
2019 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
This reveals AD as a metabolic disease that is under tight control by JNK3.
|
22958823 |
2012 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Specifically, in AD, JNK3 is the main protein kinase for APP phosphorylation, which is an important mechanism for Aβ processing, and a biomarker of Alzheimer's disease.
|
28372912 |
2017 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
The p493F12 gene maps to the human chromosome 21q21 region, a region that may be important in the pathogenesis of AD and Down's syndrome.
|
7826642 |
1995 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
It may be necessary to inhibit both the JNK1 and JNK3 simultaneously, especially as previous studies suggest that JNK3 contributes to AD neuropathology.
|
26558630 |
2016 |
|
Obesity
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Emerging evidence indicates that whereas JNK1 and JNK2 isoforms promote the development of obesity and insulin resistance, JNK3 activity protects from excessive adiposity.
|
28180059 |
2017 |
|
Obesity
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, by use of novel and highly selective JNK inhibitors, we investigated the actions of JNK in the control of feeding and body weight homeostasis.In lean mice, intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration of SR-3306, a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor, reduced food intake and body weight.Moreover, i.p. and i.c.v. administrations of SR11935, a brain-penetrant and JNK2/3 isoform-selective inhibitor, exerted similar anorectic effects as SR3306, which suggests JNK2 or JNK3 mediates aspect of the anorectic effect by pan-JNK inhibition.Furthermore, daily i.p. injection of SR3306 (7 days) prevented the increases in food intake and weight gain in lean mice upon high-fat diet feeding, and this injection paradigm reduced high-fat intake and obesity in diet-induced obese (DIO) mice.
|
28165482 |
2017 |
|
Parkinson Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overall, these results concluded that rasagiline has the ability to inhibit the expression of JNK3 and upregulate caspase‑3 in early stages of PD; however, rasagline appears to have no impact on JNK3 and caspase‑3 levels in the advanced stages of PD.
|
29257285 |
2018 |
|
Parkinson Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of PI3K-Akt-mTOR signaling pathway leads to a decrease in the expression of JNK3, which protects dopaminergic neurons and improves PD.
|
30783448 |
2019 |
|
Anorexia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, by use of novel and highly selective JNK inhibitors, we investigated the actions of JNK in the control of feeding and body weight homeostasis.In lean mice, intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration of SR-3306, a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor, reduced food intake and body weight.Moreover, i.p. and i.c.v. administrations of SR11935, a brain-penetrant and JNK2/3 isoform-selective inhibitor, exerted similar anorectic effects as SR3306, which suggests JNK2 or JNK3 mediates aspect of the anorectic effect by pan-JNK inhibition.Furthermore, daily i.p. injection of SR3306 (7 days) prevented the increases in food intake and weight gain in lean mice upon high-fat diet feeding, and this injection paradigm reduced high-fat intake and obesity in diet-induced obese (DIO) mice.
|
28165482 |
2017 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mitogen-activated protein kinase (MAPK) signaling plays an important role in inflammatory diseases such as rheumatoid arthritis (RA).The aim of our study was to elucidate the therapeutic potential of the highly selective p38 MAPK inhibitor Skepinone-L and the dual inhibitor LN 950 (p38 MAPK and JNK 3) in the K/BxN serum transfer model of RA.
|
31037574 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RT-qPCR showed that the expression of MAPK10 in breast cancer tissues was significantly lower than that in adjacent tissues, while it was reciprocal in expression of miR-21. miR-21-5p negatively regulated MAPK10.
|
31375553 |
2019 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genes expressed at higher levels in tFL than EBV(-)BL and EBV(+)BL included calcium/calmodulin-dependent protein kinase I (CAMK1) and mitogen-activated protein kinase 10 (MAPK10).
|
12967475 |
2003 |